Stock RELYPSA INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Relypsa Inc Stock

Equities

US7595311066

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Relypsa Inc

Press releases Relypsa Inc

Relypsa : Announces Publication of Results of Veltassa Drug-Drug Interaction Studies in Journal of Cardiovascular Pharmacology and Therapeutics PU
Relypsa Announces Data on the Treatment and Impact of Hyperkalemia to be Presented at ASN Kidney Week 2016 GL
Relypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia GL
Relypsa : Acquisition May Not Be in the Best Interests of RLYP Shareholders PR
RELYPSA, INC. Former SEC Attorney Willie Briscoe and Powers Taylor LLP Believe the Acquisition by Galenica May Be Unfair to Shareholders BU
More press releases

Managers and Directors - Relypsa Inc

Managers TitleAgeSince
David Bushinsky PRN
 Corporate Officer/Principal - -
Gregory Oakes PRN
 Corporate Officer/Principal 56 -
More insiders

Company Profile

More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.49% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.31% 96.73B
ARGENX SE Stock argenx SE
+1.66% 21.31B
BIONTECH SE Stock BioNTech SE
-16.16% 21.21B
GENMAB A/S Stock Genmab A/S
-6.82% 18.79B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.41% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-22.87% 13.68B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.32% 13.44B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.46% 10.98B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. Stock